-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the None sector with a price to sales ratio of 0.0.
Based on the above factors, Nautilus Biotechnology, Inc gets an overall score of 1/5.
| ISIN | US63909J1088 |
|---|---|
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 99M |
|---|---|
| PE Ratio | None |
| Target Price | 1.75 |
| Beta | 1.21 |
| Dividend Yield | None |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NAUT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
